Leaflet: information for the user
Enalapril/Lercanidipino Krka 20 mg/10 mg film-coated tablets
Enalapril maleate/Lercanidipine hydrochloride
Read this leaflet carefully before you start to take this medicine, because it contains important information for you
Contents of the pack and additional information.
Enalapril/Lercanidipino Krka is a fixed combination of an ACE inhibitor (enalapril) and a calcium channel blocker (lercanidipino), two medications that lower blood pressure.
Enalapril/Lercanidipino Krka is indicated for the treatment of high blood pressure (hypertension) in patients in whom enalapril 20 mg alone does not adequately control it. Enalapril/Lercanidipino Krka should not be used as the first treatment for hypertension.
Do not take Enalapril/Lercanidipino Krka:
Warnings and precautions.
Consult your doctor or pharmacist before starting to take Enalapril/Lercanidipino Krka.
Your doctor may monitor your renal function, blood pressure, and electrolyte levels (e.g. potassium) at regular intervals.
See also information under the heading “Do not take Enalapril/Lercanidipino Krka”.
if you are about to undergo surgery or certain treatments soon
if you are about to undergo any of the following procedures, inform your doctor that you are taking Enalapril/Lercanidipino Krka:
You should inform your doctor if you think you are (or may be) pregnant or if you are breastfeeding (see the pregnancy section).
Children and adolescents
Do not administer this medication to children and adolescents under 18 years old, as there is no information on its efficacy and safety.
Other medications and Enalapril/Lercanidipino Krka
Enalapril/Lercanidipino Krka should not be taken with certain medications.
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including those obtained without a prescription. This is because when you take Enalapril/Lercanidipino Krka simultaneously with certain medications, the effect of Enalapril/Lercanidipino Krka or the other medications may be intensified or weakened, or certain adverse effects may occur more frequently.
Specifically, inform your doctor or pharmacist if you are taking any of the following medications:
See “Do not take Enalapril/Lercanidipino Krka”
Do not take enalapril/lercanidipino if you have taken or are currently taking sacubitril/valsartan, a medication used to treat chronic heart failure in adults, as the risk of angioedema (rapid swelling under the skin in areas such as the throat) is increased.
If you are taking any of the following medications, the risk of angioedema may be increased:
Your doctor may need to adjust your dose and/or take other precautions:
Taking Enalapril/Lercanidipino Krka with food, drinks, and alcohol
Take Enalapril/Lercanidipino Krka at least 15 minutes before a meal.
A fatty meal significantly increases the levels of the medication in the blood.
Alcohol may increase the effect of Enalapril/Lercanidipino Krka. Do not consume alcoholic beverages during treatment with this medication.
Enalapril/Lercanidipino Krka should not be taken with grapefruit or grapefruit juice, as it may increase its blood pressure-lowering effect (see “Do not take Enalapril/Lercanidipino Krka”).
Pregnancy, breastfeeding, and fertility
Pregnancy and fertility
You should inform your doctor if you think you are (or may be) pregnant. Your doctor will usually recommend that you stop taking Enalapril/Lercanidipino Krka before becoming pregnant or as soon as you know you are pregnant and recommend that you take another medication instead of Enalapril/Lercanidipino Krka. Enalapril/Lercanidipino Krka is not recommended for use during the first months of pregnancy, and in any case, it should not be administered after the third month of pregnancy, as it may cause serious harm to your baby when administered from that point onwards.
Breastfeeding
Enalapril/Lercanidipino Krka should not be taken during breastfeeding.
Consult your doctor or pharmacist if you are taking, before taking any medication.
Driving and operating machinery
If you experience dizziness, weakness, fatigue, or somnolence while taking this medication, do not drive or operate hazardous machinery.
Enalapril/Lercanidipino Krka contains lactose and sodium
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medication.
This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist.In case of doubt, consult your doctor or pharmacist again.
Adults: Unless your doctor tells you otherwise, the usual dose is one tablet per day, every day, and always at the same time. It is preferable to take it in the morning 15 minutes before breakfast. The tablets should be swallowed whole with water. See “Taking Enalapril/Lercanidipino Krka with food, drinks, and alcohol”.
Patients with kidney problems/advanced age:Your doctor will decide the medication dose you should take, taking into account how well your kidneys are functioning.
If you take more Enalapril/Lercanidipino Krka than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20 indicating the medication and the amount ingested.
It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
Taking more than the correct dose may cause your blood pressure to drop too low and your heart to beat irregularly or more rapidly.
If you forgot to take Enalapril/Lercanidipino Krka
If you forget to take your tablet, do not take the missed dose. Take the next doses at your usual time. Do not take a double dose to make up for the missed doses.
If you interrupt the treatment with Enalapril/Lercanidipino Krka
Do not stop taking your medication unless your doctor tells you to.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. This medicine may cause the following side effects:
Some side effects can be serious.
Inform your doctor immediately if you notice any of the following side effects:
When you start taking Enalapril/Lercanidipino Krka, you may feel weakness or dizziness, or notice that your vision becomes blurry; this is caused by a sudden drop in blood pressure, and if it happens, it will be helpful to lie down. If you are concerned, consult your doctor.
Side effects observed withEnalapril/Lercanidipino Krka
Frequent(may affect up to 1 in 10 people)
Cough, feeling of dizziness, headache.
Infrequent(may affect up to 1 in 100 people)
Changes in blood parameters, such as a decrease in platelet count, an increase in potassium levels in the blood, nervousness (anxiety), feeling of dizziness when standing up, vertigo, rapid or irregular heartbeat (palpitations), sudden redness of the face, neck, or upper chest (erythema), low blood pressure, abdominal pain, constipation, feeling sick (nausea), increased levels of liver enzymes, skin redness, joint pain, increased urination frequency, feeling weak, fatigue, feeling hot, inflammation of the ankles.
Rare(may affect up to 1 in 1,000 people)
Anemia, allergic reactions, ringing in the ears (tinnitus), fainting, dry throat, sore throat, indigestion, salty sensation in the tongue, diarrhea, dry mouth, inflammation of the gums, allergic reaction with swelling of the face, lips, tongue, or throat that causes difficulty breathing or swallowing, skin rash, urticaria, nocturia, production of large amounts of urine, impotence.
Additional side effects observed with Enalapril or Lercanidipine alone
Enalapril
Blurred vision, feeling of dizziness, weakness, feeling sick (nausea), and cough.
Frequent(may affect up to 1 in 10 people)
Depression, headache, fainting (syncope), chest pain, dizziness due to low blood pressure, changes in heart rate, rapid or irregular heartbeat (palpitations), angina, shortness of breath, alterations in taste, increased levels of creatinine in the blood (usually detected through a blood test), high levels of potassium in the blood, diarrhea, abdominal pain, fatigue (fatigue), rash, allergic reaction with swelling of the face, lips, tongue, or throat that causes difficulty breathing or swallowing.
Infrequent(may affect up to 1 in 100 people)
Anemia (including aplastic and hemolytic anemia), sudden drop in blood pressure, confusion, drowsiness or insomnia, feeling of pins and needles in the skin or numbness, vertigo (feeling of dizziness), ringing in the ears (tinnitus), rapid or irregular heartbeat (palpitations), myocardial infarction (possibly caused by very low blood pressure in certain high-risk patients, including those with heart or brain blood supply problems), stroke (possibly due to very low blood pressure in high-risk patients), nasal discharge, sore throat and hoarseness, asthma-associated chest tightness, slowed movement of food through the intestines (ileus), inflammation of the pancreas, feeling sick (vomiting), indigestion, constipation, stomach irritation (gastritis), dry mouth, ulcers, anorexia, increased sweating, itching or urticaria, hair loss, renal function alteration, renal insufficiency, high levels of protein in the urine (measured through a blood test), impotence, muscle cramps, general feeling of discomfort, high temperature (fever), high levels of urea in the blood, low levels of sugar or sodium in the blood (all measured through a blood test), sudden redness of the face, neck, or upper chest (erythema).
Rare(may affect up to 1 in 1,000 people)
Changes in blood parameters, such as a decrease in white blood cell count, bone marrow depression, autoimmune diseases, strange dreams, swollen lymph nodes in the neck, armpits, or groin, sleep disorders, Raynaud's phenomenon (in which hands and feet may become intensely cold and white due to low blood flow), pulmonary infiltrates, fluid or other substances accumulation in the lungs (visible on X-rays), nasal inflammation, pneumonia, inflammation of the cheeks, gums, tongue, lips, and throat, liver problems, such as decreased liver function, inflammation of the liver, jaundice (yellowing of the skin or eyes), increased levels of bilirubin (measured through a blood test), erythema multiforme (red spots of different shapes on the skin), Stevens-Johnson syndrome or toxic epidermal necrolysis (a severe skin condition characterized by redness, scaling, blistering, or open sores), dermatitis exfoliativa/erythroderma (severe skin rash with peeling or shedding), or pemphigus (small blisters filled with fluid on the skin), decreased urine production, gynecomastia (breast enlargement in men).
Very rare(may affect up to 1 in 10,000 people)
Frequency unknown(cannot be estimated from available data)
Excessive production of antidiuretic hormone causing fluid retention, leading to weakness, fatigue, or confusion.
A set of symptoms has been reported that may include one or more of the following: fever, inflammation of blood vessels (serositis/vasculitis), muscle pain (myalgia/miositis), joint pain (arthralgia/arthritis). It may cause a rash, photosensitivity, or other skin manifestations.
Lercanidipine
Some side effects can be serious.
Rare(may affect up to 1 in 1,000 people)
Angina pectoris (chest pain caused by lack of blood supply to the heart), allergic reactions (with symptoms such as itching, rash, urticaria), fainting.
Patients with pre-existing angina pectoris may experience an increase in frequency, duration, or severity of attacks associated with treatment with the group of medications to which lercanidipine belongs. Isolated cases of myocardial infarction have been observed.
Other possible side effects:
Frequent(may affect up to 1 in 10 people)
Headache, rapid heartbeat, feeling of rapid or irregular heartbeat (palpitations), sudden redness of the face, neck, or upper chest (rubor), swelling of the ankles.
Infrequent(may affect up to 1 in 100 people)
Dizziness, low blood pressure, heartburn, feeling sick (nausea), abdominal pain, skin rash, itching, muscle pain, increased urination frequency, weakness or fatigue.
Rare(may affect up to 1 in 1,000 people)
Drowsiness, vomiting, diarrhea, urticaria, increased urination frequency, chest pain (angina).
Frequency unknown(cannot be estimated from available data)
Swelling of the gums, changes in liver function (detected through blood tests), cloudy fluid (during hemodialysis through a tube in the abdomen), swelling of the face, lips, tongue, or throat that may cause difficulty breathing or swallowing (angioedema).
If any of the side effects worsen, or if you experience any type of side effect not listed in this prospectus, inform your doctor or pharmacist. You can consult your doctor or pharmacist for more information about side effects, as they have a more complete list of side effects.
Reporting side effects
If you experience any of the side effects, consult your doctor or pharmacist, even if they are not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date refers to the last day of the month indicated.
Do not store at a temperature above 30°C.
Store in the original packaging to protect it from moisture.
Medicines should not be disposed of through drains or in the trash. Deposit the packaging and medicines you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Enalapril/Lercanidipine Krka:
Appearance of the product and contents of the Enalapril/Lercanidipine Krka package:
Enalapril/Lercanidipine Krka 20 mg/10 mg tablets are yellow, round, slightly biconvex with beveled edges, and compressed diameter 10 mm.
Enalapril/Lercanidipine Krka 20 mg/10 mg is supplied in packaging of 10, 14, 15, 28, 30, 50, 56, 60, 84, 90, 98, and 100 film-coated tablets per carton.
Enalapril/Lercanidipine Krka 20 mg/10 mg is supplied in packaging with blisters in a calendar format: 14, 28, 56, or 98 film-coated tablets per carton.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer:
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
For more information about this medication, please contact the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., C/ Anabel Segura 10, Pta. Baja, Oficina 1, 28108 Alcobendas, Madrid, Spain
This medication is authorized in the member states of the European Economic Area with the following names:
Member state name | Medication name |
Bulgaria, Estonia, Slovakia, Latvia, Hungary, Poland, Czech Republic, Romania | Elernap |
Finland, Ireland | Enalapril/Lercanidipine Krka |
Italy | Enalapril e Lercanidipina Krka |
Slovenia, Lithuania | Elyrno |
Austria, Portugal | Lenap |
Last review date of this prospectus::January 2022
More detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.